IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

This lat­est quar­ter­ly earn­ings sea­son for phar­ma has been a time for com­pa­nies to vent about Pres­i­dent Biden’s new drug price ne­go­ti­a­tion law, with some com­pa­nies like Al­ny­lam point­ing to or­phan drug des­ig­na­tion re­stric­tions, and oth­ers like Eli Lil­ly not­ing the dis­par­i­ties be­tween small and large mol­e­cule drugs when it comes to when the ne­go­ti­a­tions kick off (9 years vs. 13 years).

But As­traZeneca and Mer­ck ex­ec­u­tives are now rais­ing con­cerns about how the IRA will im­pact can­cer drug de­vel­op­ment mov­ing for­ward as the clock for ne­go­ti­a­tions be­gins with the first ap­proved in­di­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.